

Shangzi Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6671908/publications.pdf>

Version: 2024-02-01

15
papers

1,242
citations

1307594

7
h-index

1588992

8
g-index

17
all docs

17
docs citations

17
times ranked

2516
citing authors

#	ARTICLE	IF	CITATIONS
1	Antitumor T-cell Immunity Contributes to Pancreatic Cancer Immune Resistance. <i>Cancer Immunology Research</i> , 2021, 9, 386-400.	3.4	9
2	DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma. , 2021, 9, e002837.		23
3	Abstract 6636: Therapy with BXCL701 (B), a DPP8, DPP9, DPPIV and FAP inhibitor, in combination with anti-PD1 antibody (PD1) in a syngeneic murine pancreatic ductal adenocarcinoma (PDAC) model improves treatment outcomes and induces intratumoral NK cell infiltrates and a marked reduction in tumor stromal fibrosis. , 2020, , .		1
4	Vaccine against gastrin, a polyclonal antibody stimulator, decreases pancreatic cancer metastases. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 317, G682-G693.	3.4	9
5	Abstract A096: The potential role of fibroblast activation protein as a natural killer cell immune checkpoint. , 2019, , .		1
6	Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 195-207.	4.2	25
7	Abstract LB-133: De novo expression of gastrin and CCK-B receptors in cell lines derived from KPC mice. , 2017, , .		0
8	Abstract 4023: Combination therapy with immune checkpoint inhibitor and CCK-receptor blockade increases survival of pancreatic cancer. , 2016, , .		0
9	c-Abl Modulates Tumor Cell Sensitivity to Antibody-Dependent Cellular Cytotoxicity. <i>Cancer Immunology Research</i> , 2014, 2, 1186-1198.	3.4	12
10	IL4 Limits the Efficacy of Tumor-Targeted Antibody Therapy in a Murine Model. <i>Cancer Immunology Research</i> , 2014, 2, 1103-1112.	3.4	21
11	The Clinical Potential of Targeted Nanomedicine: Delivering to Cancer Stem-like Cells. <i>Molecular Therapy</i> , 2014, 22, 278-291.	8.2	50
12	Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 49-61.	4.2	35
13	Monoclonal antibodies: versatile platforms for cancer immunotherapy. <i>Nature Reviews Immunology</i> , 2010, 10, 317-327.	22.7	1,056
14	Abstract LB-324: A toll-like receptor 4 agonist enhances the efficacy of trastuzumab therapy and promotes adaptive immunity and long-term protection against a human ErbB-2 (HER2)-transfected syngeneic tumor in a human HER2 transgenic mouse model. , 2010, , .		0
15	Abstract PL6-2: Antibody-initiated cancer immunotherapy. , 2010, , .		0